Fundz

Eradivir Secures $10 Million in Private Financing to advance its lead antiviral therapeutic, EV25. This financing round supports ongoing development efforts.

PRIVATEOct 07, 2025

Amount Raised

$10 Million

Round Type

Funding Round

West LafayetteBiotechnologyTherapeutics

Description

Eradivir Inc. has closed a $10 million private financing round to support the development of its lead antiviral therapeutic, EV25, and a second molecule, EV148, for RSV. The funding reflects strong confidence from previous investors. The funds will complete the EV25 Phase 2a study and support IND-enabling studies for EV148

Quick answer

Eradivir raised $10 Million in a Funding Round round, dated October 7, 2025. Eradivir is based in West Lafayette, Indiana, United States.

How much did Eradivir raise?
Eradivir raised $10 Million in a Funding Round round on October 7, 2025.
What does Eradivir do?
Eradivir is a preclinical biotech company focused on developing antiviral therapeutics.
Where is Eradivir based and how big is it?
Eradivir is based in West Lafayette, Indiana, United States. Fundz records about 22 employees.
Who are the decision-makers at Eradivir?
Fundz holds 2 contacts at Eradivir. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Eradivir that raised within 45 days of this round, from Fundz verified event records.

  • BeyondSpring raised $2M (Funding Round) on November 21, 2025.
  • ClearPoint Neuro raised $18M on November 20, 2025.
  • BioVaxys Technology Corp. raised $1.5M (Post-IPO Equity) on November 19, 2025.
  • VahatiCor raised $23M (Series B) on November 18, 2025.
  • FibroBiologics raised $4M on November 18, 2025.
  • Bambusa Therapeutics raised an undisclosed amount (Series A) on November 17, 2025.

Who to call at Eradivir, and when

A new round usually means Eradivir is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Eradivir raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Eradivir, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Eradivir. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Eradivir

Location

West Lafayette, Indiana, United States

About

Eradivir is a preclinical biotech company focused on developing antiviral therapeutics. Its primary product, EV25, targets influenza through a unique small-molecule, bispecific immunotherapy that enhances the immune response against disease. The company leverages innovations from Purdue University's research and has secured funding to advance its clinical trials. Eradivir aims to demonstrate the safety and efficacy of EV25 in human studies.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Eradivir raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Predictive Intelligence
Strategic

ML-powered predictions for Eradivir's next move

See what Strategic adds

Eradivir raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.